Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06156254 Recruiting - Clinical trials for COVID-19 Vaccination

Community Care Intervention to Decrease COVID-19 Vaccination Inequities

Start date: September 21, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines.

NCT ID: NCT06156137 Recruiting - COVID-19 Pneumonia Clinical Trials

Characteristics of Blood Glucose Variability in Patients With Type 2 Diabetes Mellitus and COVID-19

Start date: August 1, 2023
Study type: Observational

using intermittently scanned continuous glucose monitoring (isCGM) to clarify the characteristics of blood glucose variability parameters in T2DM patients with NCP, guide the formulation of reasonable clinical treatment measures and make timely and reasonable adjustments, improve the prognosis of patients, shorten the length of hospital stay, and reduce medical costs. The goal of this observational study is to investigate the characteristics of blood glucose variability in patients with type 2 diabetes mellitus (T2DM) complicated with novel coronavirus pneumonia (NCP) and its effect on disease progression and prognosis. The main question it aims to answer is:After fully lifting coronavirus disease 2019 (COVID-19) pandemic control measures in mainland China in 12/2022, the incidence of COVID-19 has increased markedly, making it difficult to meet the general time-in-range (TIR) requirement. Therefore, the investigators investigated a more clinically practical TIR threshold and examined its association with the prognosis of COVID-19 patients with type-2 diabetes. participant population/health conditions:Participants were equipped with isCGM sensors on admission. According to the outcome, the patients were divided into favorable outcome group and composite outcome group.

NCT ID: NCT06146361 Recruiting - COVID-19 Clinical Trials

Vale+Tú Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19

Start date: November 3, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention.

NCT ID: NCT06142201 Recruiting - COVID-19 Clinical Trials

A Real-World Study of JT001 for COVID-19

Start date: August 31, 2023
Study type: Observational

Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treated with JT001

NCT ID: NCT06128967 Recruiting - Clinical trials for Chronic Fatigue Syndrome

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Start date: October 18, 2023
Phase: Phase 3
Study type: Interventional

Date of notification letter to the IRB informing start of recruitment activities: October 21, 2023. Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals after an acute episode of COVID-19, even in those who had a mild and oligosymptomatic SARS-CoV-2 infection. Around 40% of these patients present symptoms that significantly compromise their daily activities. There is increasing evidence that LONG COVID is accompanied by dysregulated, persistent and uncontrolled inflammation, often accompanied by the development of an autoreactive immune response, including autoantibodies. Symptoms can last months or years, particularly in cases of chronic fatigue syndrome, with significant proportions of individuals having significant chronic impairment, preventing the performance of work and social activities.

NCT ID: NCT06128928 Recruiting - COVID-19 Clinical Trials

Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities

Start date: July 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to find out which approach works better in getting more of the friends and connections of Latino adults get vaccinated against COVID-19. The main questions this study aims to answer are: 1. Can teaching people to use motivational interviewing help more friends and connections of Latino adults get the COVID-19 vaccine compared to just giving information about the vaccine? 2. What are the things that make it easier or harder for Latinos and networks to get the COVID-19 vaccine? 3. How does this intervention work in practice so that it can be made available to more people in the future The researchers will compare the vaccine rates of the friends and connections of Latinos who have been trained in motivational interviewing with those who have only been given information about the COVID-19 vaccine. This will help figure out which method works best to encourage more people to get vaccinated.

NCT ID: NCT06127108 Recruiting - COVID-19 Clinical Trials

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

Start date: November 14, 2023
Phase: N/A
Study type: Interventional

The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, Roche cobas® SARS-CoV-2 (K231306) and Quidel Lyra® Influenza A+B Assay(K230236) (RT-PCR) in symptomatic patients suspected of respiratory viral infection by a healthcare provider.

NCT ID: NCT06125457 Recruiting - COVID-19 Clinical Trials

Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission

Start date: April 9, 2022
Study type: Observational

The management of patients with a selective IgA deficiency currently consists of symptomatic treatment with treatment of infections by occasional or prolonged antibiotic therapy, immunosuppressive treatments for autoimmune pathologies, symptomatic treatment of allergic manifestations. IVIG supplements are sometimes proposed in the event of recurrent infections and the demonstration of deficiencies in IgG subclasses (IgG1, 2, 3) often not sought for diagnosis The factors associated with the severity of clinical manifestations are not well identified and patients with IgA deficiency must be monitored over the long term because of the risk of the appearance of autoimmune manifestations and neoplasia. The identification of such factors could lead to the proposal of close monitoring for these patients. IgA deficiency, which is frequent, has not been identified as a risk factor for severe COVID-19 infection, probably due to a lack of studies with sufficient recruitment. The therapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19 infection is therefore not consensual. There is currently no action to be taken regarding the risk of transmission of IgA deficiency.

NCT ID: NCT06124638 Recruiting - COVID-19 Clinical Trials

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A&B Panel Self Test in the hands of patients/lay-users. Nasal swabs will be self-collected by subjects/lay-users who are symptomatic and suspected of viral respiratory infection. They will perform, read, and interpret the test result. The test is intended for nonprescription home use for qualitative detection of COVID-19, Influenza A antigen, and Influenza B antigen.

NCT ID: NCT06124131 Recruiting - COVID-19 Clinical Trials

Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Start date: November 11, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are: - Do patient financial incentives for completing colorectal cancer screening increase screening completion? - Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots? Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment. Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.